PapersFlow Research Brief
Treatment of Major Depression
Research Guide
What is Treatment of Major Depression?
Treatment of Major Depression encompasses antidepressant medications, ketamine and NMDA receptor antagonists, cognitive therapy, and multistep strategies for treatment-resistant cases, targeting neurobiological mechanisms like glutamate signaling and synaptic plasticity.
The field includes 58,789 works focused on molecular mechanisms and treatment strategies for depression. Key assessments such as 'The PHQ-9' by Kroenke et al. (2001) and 'A New Depression Scale Designed to be Sensitive to Change' by Montgomery and Åsberg (1979) enable measurement of treatment effects. Clinical trials like 'Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report' by Rush et al. (2006) show lower remission rates with additional treatment steps.
Topic Hierarchy
Research Sub-Topics
Treatment-Resistant Depression
This sub-topic investigates definitions, prevalence, and management of treatment-resistant depression (TRD) failing standard antidepressants. Researchers evaluate augmentation strategies, predictors, and novel biomarkers.
Ketamine in Depression Treatment
This sub-topic examines ketamine's rapid antidepressant effects via NMDA receptor antagonism and clinical protocols for TRD. Researchers study safety, dosing regimens, and long-term efficacy through RCTs.
Glutamate Signaling in Depression
This sub-topic explores dysregulated glutamatergic neurotransmission in depression pathophysiology and as therapeutic targets. Researchers use neuroimaging and pharmacology to link glutamate to synaptic dysfunction.
Synaptic Plasticity and Depression
This sub-topic studies impaired synaptic plasticity mechanisms underlying depression and antidepressant actions promoting synaptogenesis. Researchers integrate animal models with human postmortem and imaging data.
NMDA Receptor Antagonists
This sub-topic covers pharmacological development of NMDA antagonists beyond ketamine for depression, including rapastinel and esketamine. Researchers assess dissociative side effects, mechanisms, and Phase III outcomes.
Why It Matters
Treatment approaches address substantial symptom severity and role impairment in major depressive disorder, which affects a wide population segment as documented in 'The Epidemiology of Major Depressive Disorder' by Kessler et al. (2003). The STAR*D trial in 'Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report' by Rush et al. (2006) revealed that patients needing third or fourth treatment steps had lower acute remission rates and higher relapse rates during follow-up, guiding personalized multistep sequences. Cognitive therapy matches medication efficacy for acute effects, per 'Cognitive Therapy for Depression' (2012), supporting its use in clinical guidelines to improve outcomes in treatment-resistant depression.
Reading Guide
Where to Start
'The PHQ-9' by Kroenke et al. (2001), as it provides a foundational, widely used tool for assessing depression severity and treatment response in clinical settings.
Key Papers Explained
'The Epidemiology of Major Depressive Disorder' by Kessler et al. (2003) establishes prevalence and impairment, building to 'Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication' by Kessler et al. (2005) which details lifetime risks and youth onset. 'Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report' by Rush et al. (2006) applies this to real-world multistep treatments, while 'Cognitive Therapy for Depression' (2012) and 'Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies' by Lang and Borgwardt (2013) explore therapeutic mechanisms.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research emphasizes multistep strategies for treatment-resistant cases and metabolic links to depression, as in Lang and Borgwardt (2013), with no recent preprints or news indicating ongoing focus on glutamate and synaptic plasticity pathways.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | “Mini-mental state” | 1975 | Journal of Psychiatric... | 85.7K | ✕ |
| 2 | The PHQ-9 | 2001 | Journal of General Int... | 41.5K | ✓ |
| 3 | Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV D... | 2005 | Archives of General Ps... | 20.1K | ✕ |
| 4 | A New Depression Scale Designed to be Sensitive to Change | 1979 | The British Journal of... | 13.6K | ✕ |
| 5 | Cognitive Therapy for Depression | 2012 | PsycEXTRA Dataset | 9.7K | ✕ |
| 6 | ECDEU Assessment Manual for Psychopharmacology | 1976 | Internet Archive (Inte... | 8.8K | ✕ |
| 7 | Molecular Mechanisms of Depression: Perspectives on New Treatm... | 2013 | Cellular Physiology an... | 8.5K | ✓ |
| 8 | The Epidemiology of Major Depressive Disorder | 2003 | JAMA | 7.9K | ✕ |
| 9 | Acute and Longer-Term Outcomes in Depressed Outpatients Requir... | 2006 | American Journal of Ps... | 5.3K | ✕ |
| 10 | The PHQ-8 as a measure of current depression in the general po... | 2008 | Journal of Affective D... | 4.9K | ✕ |
Frequently Asked Questions
What is the PHQ-9 used for in depression treatment?
'The PHQ-9' by Kroenke et al. (2001) serves as a validated tool to measure depression severity in primary care and general populations. It supports tracking treatment response and outcomes. The related 'The PHQ-8 as a measure of current depression in the general population' by Kroenke et al. (2008) adapts it for broader screening.
How does cognitive therapy perform compared to medication for depression?
'Cognitive Therapy for Depression' (2012) states that cognitive therapy achieves acute effects equivalent to medication. It also details mechanisms of change and dissemination strategies. Long-term effectiveness supports its role alongside pharmacotherapy.
What outcomes occur in multistep treatment for depression?
Rush et al. (2006) in 'Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report' found lower acute remission rates, particularly in third and fourth steps, with higher relapse during follow-up. This underscores the need for tailored sequences. Studies should identify optimal paths for individuals.
What scale detects treatment changes in depression?
Montgomery and Åsberg (1979) developed 'A New Depression Scale Designed to be Sensitive to Change' from ratings of 54 English and 52 Swedish patients. It identifies 17 common symptoms in primary depression. The scale proves sensitive to treatment effects.
What are molecular mechanisms linked to depression treatment?
Lang and Borgwardt (2013) in 'Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies' associate depression with metabolic issues like obesity, diabetes, and poor glycemic control. These links suggest targets for new strategies. The paper connects depression risk to cancer, dementia, epilepsy, and stroke.
How prevalent is major depressive disorder?
Kessler et al. (2003) in 'The Epidemiology of Major Depressive Disorder' describe it as common with substantial impairment. Kessler et al. (2005) in 'Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication' report half of Americans meet DSM-IV criteria lifetime, with onset in youth.
Open Research Questions
- ? How can treatment sequences be optimized to improve remission rates in patients requiring third or fourth steps?
- ? What molecular pathways beyond glutamate signaling offer new targets for treatment-resistant depression?
- ? Which early interventions prevent progression given youth onset of disorders?
- ? How do metabolic factors like insulin sensitivity influence antidepressant response?
Recent Trends
The field maintains 58,789 works with no specified 5-year growth rate; emphasis persists on established tools like PHQ-9 (41,528 citations) and STAR*D outcomes showing step-dependent remission declines, per Rush et al. , alongside metabolic perspectives from Lang and Borgwardt (2013).
2006No recent preprints or news coverage available.
Research Treatment of Major Depression with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Treatment of Major Depression with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers